YOLFTbeta
Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc Common Stock

CURX · NASDAQ · Healthcare / Biotechnology

4.80USD-0.87 (-15.34%)

Price History

Full chart

Market Stats

Previous Close5.67
Open4.82
Day Range4.59 – 4.82
52-Week Range3.58 – 16.93
Volume6.30K
Market Cap6.98M
P/E (TTM)0.00
Forward P/E0.00
EPS-7.38
Dividend Yield0.00%
50-Day Avg4.35
200-Day Avg6.55

About

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023. Curanex Pharmaceuticals Inc was founded in 1996 and is headquartered in Jericho, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Jun Liu
  • Employees6
  • Headquarters2 Jericho Plaza, Jericho, NY, United States, 11753, USA
  • Websitehttps://www.curanexpharma.com

Leadership

  • Mr. Jun LiuCEO, President & Chairman · b. 1964
  • Mr. Wanjun ZhangChief Financial Officer & Treasurer · b. 1974
  • Dr. Liqin Xie Ph.D.Chief Operating Officer · b. 1972
  • Dr. Ning Zhang Ph.D.Chief Technology Officer · b. 1976
  • Dr. Huijuan Zhong Ph.D.Chief Science Officer & Director · b. 1967
  • Ms. Dian Ying JingSecretary · b. 1967

Financials

Income Statement

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Revenue26.00K000
Growth (%)--100.00%--
Cost of Revenue21.57K0--
Gross Profit4.43K0--
Gross Margin17.03%---
Operating Expense24.66K19.30K--
Operating Income-20.23K-19.30K-365.06K-4.24M
Operating Margin-77.82%---
EBITDA925-17.48K-290.39K-4.22M
EBITDA Margin3.56%---
Net Income-20.23K-19.20K-361.51K-4.23M
Net Income Margin-77.82%---
R&D--02.99M
Interest Expense--08.54K

Balance Sheet

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Total Assets10.23K74.37K517.93K11.58M
Total Liabilities014.28K14.57K361.04K
Total Equity10.23K60.09K503.36K11.22M
Cash2.43K74.37K148.89K4.97M
Total Debt---346.70K
Net Debt--74.37K-148.89K-4.63M

Cash Flow

Currency: USD2022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow3.34K-120-555.58K-10.48M
Financing Cash Flow-3.00K72.06K630.10K15.31M
Capital Expenditure0050
Free Cash Flow3.34K-120-555.58K-10.48M
FCF to OCF100.00%100.00%100.00%100.00%

Earnings

Report DateJul 1, 2025Nov 17, 2025Dec 31, 2025Mar 31, 2026Aug 14, 2026Nov 13, 2026
EPS Estimate0.00-----
EPS Actual-0.01-0.04-2.17-2.22-0.03-
Surprise------
Timing------

Key Statistics & Ratios

Market Cap6.98M
Enterprise Value4.36M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.47
EPS-7.38
Book Value3.38
Revenue (TTM)0
Gross Profit (TTM)-7.84M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-411.08%
Return on Assets-225.06%
Shares Outstanding1.57M
Shares Float505.63K
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
1.06%
Insiders
61.35%
Retail / Other
37.59%

Top Institutional Holders

  • Geode Capital Management, LLC
    111.13K0.35%
  • Citadel Advisors Llc
    95.26K0.30%
  • TWO SIGMA SECURITIES, LLC
    56.65K0.18%
  • XTX Topco Ltd
    51.29K0.16%
  • Two Sigma Investments LLC
    27.35K0.09%
  • Citigroup Inc
    19.33K0.06%
  • Ground Swell Capital, LLC
    12.64K0.04%
  • Jump Financial LLC
    10.55K0.03%
  • UBS Group AG
    8.00K0.03%
  • DRW Securities, LLC
    00.00%
  • Jane Street Group LLC
    00.00%
  • Renaissance Technologies Corp
    00.00%
  • Bank of America Corp
    00.00%
  • HRT FINANCIAL LLC
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    23.33K0.07%
  • Fidelity Nasdaq Composite Index
    14.96K0.05%

Stock Splits

  • Aug 20, 20261:20